Catalyst Pharm Inc (CPRX) Stock Price, Quote & News

Company Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 420 3200

Website: catalystpharma.com

Address:

355 Alhambra Circle, Suite 801, Coral Gables, United States

Iightning Dec. 5 at 4:18 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.28 Exit: 0.49 Return: +78.09% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:06 PM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.28 Exit: 0.49 Return: +78.09% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

StillWaiting101 Dec. 4 at 9:02 PM

$CPRX if we are going to perfectly follow XBI on red days, we should also get some kind of move up on 1% green days for XBI or I call shenanigans

0 · Reply

toradio Dec. 4 at 7:15 PM

$CPRX Gotta luv the red to green thing closed the gap from this morning, and yesterday morning... time to move upward and onward...

0 · Reply

Iightning Dec. 4 at 5:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.40 Exit: 0.75 Return: +88.69% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Johnny_Lever Dec. 3 at 5:36 PM

$CPRX Appears to be reversing course after a back-test of the recent break-out.

0 · Reply

111ggg Dec. 3 at 2:25 PM

$CPRX Again we are entering garbage zone for this stock. To management...sell or take the company private.

0 · Reply

Iightning Dec. 2 at 12:01 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $CPRX **Contract:** Dec 19 $25C **Entry:** 0.31 **Exit:** 0.60 **Return:** **+92.76% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

StillWaiting101 Dec. 1 at 8:49 PM

$CPRX 3% down based on XBI when we don't even follow it at all on green days? Lol what

1 · Reply

111ggg Dec. 1 at 2:33 PM

$CPRX Do we see 22 or 24 first?

0 · Reply

Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 24, 2025, 8:03 AM EST - 10 days ago

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Nov 19, 2025, 8:03 AM EST - 15 days ago

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Nov 18, 2025, 8:03 AM EST - 16 days ago

Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 6, 2025, 8:36 PM EST - 4 weeks ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:06 PM EST - 4 weeks ago

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:03 PM EST - 4 weeks ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

Nov 3, 2025, 8:03 AM EST - 4 weeks ago

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

Oct 22, 2025, 8:03 AM EDT - 6 weeks ago

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 8:03 AM EDT - 2 months ago

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

Oct 1, 2025, 8:03 AM EDT - 2 months ago

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

Aug 28, 2025, 8:03 AM EDT - 3 months ago

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:12 PM EDT - 3 months ago

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 25, 2025, 8:03 AM EDT - 3 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

Aug 7, 2025, 2:21 PM EDT - 4 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:13 PM EDT - 4 months ago

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Aug 6, 2025, 8:03 AM EDT - 4 months ago

Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)

Aug 4, 2025, 8:03 AM EDT - 4 months ago

Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

Jul 22, 2025, 8:03 AM EDT - 4 months ago

Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:08 AM EDT - 6 months ago

Strong Inflows Make Catalyst Stock an Outlier

Jun 11, 2025, 7:00 AM EDT - 6 months ago

20 stocks you should avoid — no matter how well the market does

CORT CRK CRNC DDD LUMN LYV MGPI

Jun 2, 2025, 8:03 AM EDT - 6 months ago

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

May 31, 2025, 5:18 AM EDT - 6 months ago

Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma

May 8, 2025, 12:02 PM EDT - 7 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:14 PM EDT - 7 months ago

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 8:03 AM EDT - 7 months ago

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Apr 22, 2025, 8:03 AM EDT - 8 months ago

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 8, 2025, 8:06 AM EDT - 8 months ago

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Apr 3, 2025, 4:50 PM EDT - 8 months ago

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

AMGN AZN VEEV

Mar 26, 2025, 8:12 AM EDT - 9 months ago

Strong Revenue, Drug Performance Lift Catalyst Shares

Mar 11, 2025, 4:05 AM EDT - 9 months ago

Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts

Mar 4, 2025, 8:03 AM EST - 9 months ago

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 3, 2025, 2:39 PM EST - 9 months ago

Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges

Feb 27, 2025, 2:35 PM EST - 10 months ago

Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today

Feb 27, 2025, 12:29 PM EST - 10 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:13 PM EST - 10 months ago

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 8:03 AM EST - 10 months ago

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Feb 7, 2025, 3:56 PM EST - 10 months ago

Catalyst Remains a Big Money Favorite

Jan 23, 2025, 8:03 AM EST - 11 months ago

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Jan 21, 2025, 8:19 AM EST - 11 months ago

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Jan 13, 2025, 8:30 AM EST - 11 months ago

Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE

Jan 8, 2025, 12:30 PM EST - 11 months ago

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Dec 16, 2024, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Nov 13, 2024, 8:03 AM EST - 1 year ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Nov 7, 2024, 10:34 AM EST - 1 year ago

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:12 PM EST - 1 year ago

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

Oct 8, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

Oct 1, 2024, 8:03 AM EDT - 1 year ago

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024

Iightning Dec. 5 at 4:18 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.28 Exit: 0.49 Return: +78.09% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 10:06 PM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.28 Exit: 0.49 Return: +78.09% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

StillWaiting101 Dec. 4 at 9:02 PM

$CPRX if we are going to perfectly follow XBI on red days, we should also get some kind of move up on 1% green days for XBI or I call shenanigans

0 · Reply

toradio Dec. 4 at 7:15 PM

$CPRX Gotta luv the red to green thing closed the gap from this morning, and yesterday morning... time to move upward and onward...

0 · Reply

Iightning Dec. 4 at 5:46 AM

1ightning® Premium Options Alert (Actionable) Ticker: $CPRX Contract: Dec 19 $25C Entry: 0.40 Exit: 0.75 Return: +88.69% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Johnny_Lever Dec. 3 at 5:36 PM

$CPRX Appears to be reversing course after a back-test of the recent break-out.

0 · Reply

111ggg Dec. 3 at 2:25 PM

$CPRX Again we are entering garbage zone for this stock. To management...sell or take the company private.

0 · Reply

Iightning Dec. 2 at 12:01 AM

0 · Reply

StillWaiting101 Dec. 1 at 8:49 PM

$CPRX 3% down based on XBI when we don't even follow it at all on green days? Lol what

1 · Reply

111ggg Dec. 1 at 2:33 PM

$CPRX Do we see 22 or 24 first?

0 · Reply

Night_Owl_Biotech Nov. 30 at 10:28 PM

Of the 169 new commercial-stage non-oncology focused bios (attached) since 1/1/2013. 1. 53 were acquired. 27 of these were acquired @ gains versus their share price as of the day after approval. 26 were acquired @ losses. 2. 21 went bankrupt or were delisted where shareholders lost 99%+ 3. 95 are still independent. 38 of the 95 trade @ higher share prices today than at approval. 57 trade @ lower share prices today. 4. Had you purchased shares in all 169, you would be up (or have sold at M&A) in 65 of the 169. You'd be down or have otherwise lost in 104 of the 169. Like their oncology focused peers, shareholders gain ~85% of the time in those comm'l-stage non-oncology focused bios that sell within 36 months of FDA approval (24 months in oncology). There are the 15% exceptions. It's possible we missed a split. Please note or share any observations (any misses) Biggest winners since approval: $INSM (up 1,200%) $VCEL (up 1,050%) $CPRX (up 745%) $LQDA $ADMA

2 · Reply

111ggg Nov. 26 at 3:34 PM

$CPRX Lets try some more negativity.... this stock sucks and is dead money. It should now turn green.

0 · Reply

Iightning Nov. 26 at 2:52 AM

1ightning® Options Trade Alert (Actionable) | Buy $CPRX Dec 19 $25 Call | Enter: $0.54 Exit: $0.69 | Profit: 28.13% ROI | https://1ightning.com

0 · Reply

Viking0919 Nov. 25 at 5:02 PM

$CPRX

0 · Reply

111ggg Nov. 25 at 3:11 PM

$CPRX you should all thank me. My not so optimistic posts always produce positve results

0 · Reply

Iightning Nov. 25 at 12:56 PM

1ightning® Options Trade Alert (Actionable) | Buy $CPRX Dec 19 $25 Call | Enter: $0.54 Exit: $0.69 | Profit: 28.13% ROI | https://1ightning.com

0 · Reply

William2057 Nov. 25 at 2:37 AM

$CPRX Deloitte recognition: The company was recognized on the 2025 Deloitte Technology Fast 500™ list. Citi conference: Catalyst Pharmaceuticals is scheduled to participate in Citi's 2025 Global Healthcare Conference on December 2, 2025. Financial outlook: Analysts predict strong future growth, with projected revenues of over $709 million by 2028.

0 · Reply

William2057 Nov. 25 at 2:37 AM

$CPRX On November 24, 2025, Catalyst Pharmaceuticals announced its participation in the upcoming Bank of America CNS Therapeutics Virtual Conference and filed SEC forms related to executive ownership changes. The company will be presenting at the conference on December 8, 2025. Additionally, officer Brian Elsbernd acquired shares of the company, and another filing was made by Michael Wayne Kalb. News and filings on November 24, 2025 Conference participation: Catalyst Pharmaceuticals announced it will participate in the Bank of America CNS Therapeutics Virtual Conference on December 8, 2025. President and CEO Rich Daly and other management members will attend. Executive stock purchase: A Form 4 filing disclosed that officer Brian Elsbernd acquired 3,131 shares of Catalyst Pharmaceuticals (CPRX). SEC filings: A separate Form 4 filing was submitted by Michael Wayne Kalb. Other recent news

0 · Reply

Iightning Nov. 25 at 1:51 AM

1ightning® Options Trade Alert (Actionable) | Buy $CPRX Dec 19 $25 Call | Enter: $0.54 Exit: $0.69 | Profit: 28.13% ROI | https://1ightning.com

0 · Reply

Splashavelle Nov. 25 at 12:32 AM

$CPRX ready for the next leg up

0 · Reply

aristocks Nov. 25 at 12:14 AM

$CAPR well folks.. sometime you win $EXAS $NKTR $ARQT …and sometimes you loose $CAPR $CPRX

1 · Reply

vu_jade Nov. 24 at 8:58 PM

$CPRX decent chart

0 · Reply

Market Cap	2.78B
Revenue (ttm)	491.73M
Net Income (ttm)	163.89M
EPS (ttm)	N/A
PE Ratio	8.87
Forward PE	9.49
Profit Margin	33.33%
Debt to Equity Ratio	0.00

Volume	960,800
Avg Vol	1,341,632
Day's Range	N/A - N/A
Shares Out	122.91M
Stochastic %K	44%
Beta	0.69
Analysts	Strong Sell
Price Target	$34.50